Engineered extracellular vesicles and their mimics in cardiovascular diseases

Lai, Jialin; Huang, Chaobo; Guo, Yuxuan; Rao, Lang

doi:10.1016/j.jconrel.2022.04.046

Cited by 30 publications

(18 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent developments in the fields of nanotechnology and bioengineering afford valuable approaches that can dramatically improve the safety and efficacy of cancer ICB therapy. ,, With the assistance of biomaterials, multiple strategies can synergistically fight against tumors, including enhancing ICB response, such as induction of immunogenic cell death (ICD), modulation of the TME, promotion of antigen presentation, as well as reducing side effects, such as lowering the irAEs of systemic administration, expansion of the route of administration, and broaden diverse ICB modalities. ,− …”

Section: Strategies Using Biomaterials To Enhance Immune Response And...mentioning

confidence: 99%

Boosting Checkpoint Immunotherapy with Biomaterials

et al. 2023

Self Cite

View full text Add to dashboard Cite

The immune checkpoint blockade (ICB) therapy has revolutionized the field of cancer treatment, while low response rates and systemic toxicity limit its clinical outcomes. With the rapid advances in nanotechnology and materials science, various types of biomaterials have been developed to maximize therapeutic efficacy while minimizing side effects by increasing tumor antigenicity, reversing immunosuppressive microenvironment, amplifying antitumor immune response, and reducing extratumoral distribution of checkpoint inhibitors as well as enhancing their retention within target sites. In this review, we reviewed current design strategies for different types of biomaterials to augment ICB therapy effectively and then discussed present representative biomaterial-assisted immune modulation and targeted delivery of checkpoint inhibitors to boost ICB therapy. Current challenges and future development prospects for expanding the ICB with biomaterials were also summarized. We anticipate this review will be helpful for developing emerging biomaterials for ICB therapy and promoting the clinical application of ICB therapy.

show abstract

Section: Strategies Using Biomaterials To Enhance Immune Response And...mentioning

confidence: 99%

Boosting Checkpoint Immunotherapy with Biomaterials

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…This approach holds great potential for promoting more efficient patch assimilation with the host, containing the tissue substitute component necessary for function restoration, while applying spatial, concentrated EV-based cell signaling at the interface. Incorporation of functional EVs, either natural [ 84 , 85 ] or modified [ 86 , 87 ] within the proposed design and examination in a cardiac injury animal model is required to further evaluate the efficacy of this approach.…”

Section: Discussionmentioning

confidence: 99%

Three-Dimensional Bio-Printed Cardiac Patch for Sustained Delivery of Extracellular Vesicles from the Interface

Bar

Kryukov

Cohen

2022

Gels

View full text Add to dashboard Cite

Cardiac tissue engineering has emerged as a promising strategy to treat infarcted cardiac tissues by replacing the injured region with an ex vivo fabricated functional cardiac patch. Nevertheless, integration of the transplanted patch with the host tissue is still a burden, limiting its clinical application. Here, a bi-functional, 3D bio-printed cardiac patch (CP) design is proposed, composed of a cell-laden compartment at its core and an extracellular vesicle (EV)-laden compartment at its shell for better integration of the CP with the host tissue. Alginate-based bioink solutions were developed for each compartment and characterized rheologically, examined for printability and their effect on residing cells or EVs. The resulting 3D bio-printed CP was examined for its mechanical stiffness, showing an elastic modulus between 4–5 kPa at day 1 post-printing, suitable for transplantation. Affinity binding of EVs to alginate sulfate (AlgS) was validated, exhibiting dissociation constant values similar to those of EVs with heparin. The incorporation of AlgS-EVs complexes within the shell bioink sustained EV release from the CP, with 88% cumulative release compared with 92% without AlgS by day 4. AlgS also prolonged the release profile by an additional 2 days, lasting 11 days overall. This CP design comprises great potential at promoting more efficient patch assimilation with the host.

show abstract

“…During the vessel wall injury, circulating platelets can interact with collagen, vWF, and fibrin on the exposed subendothelial extracellular matrix (ECM) through GPVI, GPIb/V/IX, and GPIIb/IIIa to adhere to the injured vessels, resulting in potentiating platelet activation cascade for blood coagulation. − Such intrinsic targeting ability has motivated the use of platelet membrane-coated nanosystems for the treatments of various vascular diseases. − Among them, the process of atherosclerosis development always accompanies with endothelial activation and leukocyte infiltration due to accumulation of lipids at the vascular wall . In addition to above multifactor receptor–ligand interactions with injured vessels, P-selectin overexpressed on platelet membranes-biomimetic nanoparticles provides a high specificity to PSGL-1 upregulated on both activated endothelial cells and infiltrated leukocytes .…”

Section: Biomimetic Platelet-inspired Nanotherapeuticsmentioning

confidence: 99%

“…, stem cells, cancer cells, erythrocytes, and leukocytes), platelets with few antigens have a comprehensive advantage in respects of easy availability, low immunogenicity, and long circulation time in the blood . Therefore, the subendothelial adhesion, ligand recognition, pathogen interaction, and targeting capacity of platelet make it suitable to be used as promising biomimetic materials for disease theranostics. − For instance, by virtue of the numerous functional biomarkers on platelets ( e.g. , CD47 membrane protein, glycoprotein VI (GPVI) and P-selectin), platelets have been found to play pivotal roles in multiple physiological processes in the body, such as hemostasis, wound repair, immune response, tissue regeneration, as well as bacterial clearance. − …”

mentioning

confidence: 99%

Platelet-Inspired Nanotherapeutics for Biomedical Applications

Yang

Kong

et al. 2023

ACS Materials Lett.

View full text Add to dashboard Cite

Platelets, as abundant corpuscles in the blood, are extensively involved in normal physiological processes and disease occurrence. Recently, remarkable progress in plateletbased nanotherapeutics has been made, especially with the burgeoning fields of biotechnology and nanomedicine. Herein, we aim to provide an overview on platelet-inspired nanotherapeutics for biomedical applications. First, the recent trends of biomimetic platelet-inspired nanotherapeutics are outlined, mainly including platelet membrane-camouflaged nanosystems, platelets loading with nanoparticles and platelet-mimicking nanocarriers. Then, the emerging nanotherapeutics for functional modulation of platelet aggregation, activation, and inhibition are discussed. Subsequently, platelet derivative-based nanotherapeutics are presented, including platelet extracellular vesicles and platelet polyphosphates. Finally, the clinical application prospects of these emerging nanotherapeutics are highlighted, with particular emphasis on their rationale, advantages, and challenges.

show abstract

Engineered extracellular vesicles and their mimics in cardiovascular diseases

Cited by 30 publications

References 121 publications

Boosting Checkpoint Immunotherapy with Biomaterials

Boosting Checkpoint Immunotherapy with Biomaterials

Three-Dimensional Bio-Printed Cardiac Patch for Sustained Delivery of Extracellular Vesicles from the Interface

Platelet-Inspired Nanotherapeutics for Biomedical Applications

Contact Info

Product

Resources

About